Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 983

1.

RE-CIRCUIT: uninterrupted anticoagulation with dabigatran to cover left atrial ablation procedures.

Camm AJ.

Cardiovasc Res. 2018 Oct 1;114(12):e89-e90. doi: 10.1093/cvr/cvy204. No abstract available.

PMID:
31346598
2.

Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation.

Boriani G, Blomström-Lundqvist C, Hohnloser SH, Bergfeldt L, Botto GL, Capucci A, Lozano IF, Goette A, Israel CW, Merino JL, Camm AJ.

Europace. 2019 Jul 19. pii: euz193. doi: 10.1093/europace/euz193. [Epub ahead of print]

PMID:
31324921
3.

Outcomes in newly diagnosed atrial fibrillation and history of acute coronary syndromes: insights from GARFIELD-AF.

Verheugt FW, Ambrosio G, Atar D, Bassand JP, Camm AJ, Costabel JP, Fitzmaurice DA, Illingworth L, Goldhaber SZ, Goto S, Haas S, Jansky P, Kayani G, Stepinska J, Turpie AG, van Eickels M, Kakkar AK; GARFIELD-AF Investigators.

Am J Med. 2019 Jul 12. pii: S0002-9343(19)30543-1. doi: 10.1016/j.amjmed.2019.06.008. [Epub ahead of print]

PMID:
31306621
4.

The New CHEST Guidelines on Antithrombotic Therapy for Atrial Fibrillation Should Consider Recent Data on Rivaroxaban.

Kim YH, Shim J, Tsai CT, Wang CC, Vilela G, Muengtaweepongsa S, Kurniawan M, Maskon O, Hsu LF, Nguyen TH, Sim K, Camm AJ.

Chest. 2019 Jun;155(6):1309-1311. doi: 10.1016/j.chest.2019.03.036. No abstract available.

PMID:
31174652
5.

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER).

Beyer-Westendorf J, Camm AJ, Fox KAA, Le Heuzey JY, Haas S, Turpie AGG, Virdone S, Kakkar AK; RIVER Registry Investigators.

Thromb J. 2019 Apr 25;17:7. doi: 10.1186/s12959-019-0195-7. eCollection 2019.

6.

Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF.

Haas S, Camm AJ, Bassand JP, Angchaisuksiri P, Cools F, Corbalan R, Gibbs H, Jacobson B, Koretsune Y, Mantovani LG, Misselwitz F, Panchenko E, Ragy HI, Stepinska J, Turpie AG, Sawhney JP, Steffel J, Lim TW, Pieper KS, Virdone S, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators.

Am Heart J. 2019 Jul;213:35-46. doi: 10.1016/j.ahj.2019.03.013. Epub 2019 Apr 11.

7.

Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry.

Corbalan R, Bassand JP, Illingworth L, Ambrosio G, Camm AJ, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators.

JAMA Cardiol. 2019 Jun 1;4(6):526-548. doi: 10.1001/jamacardio.2018.4729.

PMID:
31066873
8.

EHRA White Paper: knowledge gaps in arrhythmia management-status 2019.

Goette A, Auricchio A, Boriani G, Braunschweig F, Terradellas JB, Burri H, Camm AJ, Crijns H, Dagres N, Deharo JC, Dobrev D, Hatala R, Hindricks G, Hohnloser SH, Leclercq C, Lewalter T, Lip GYH, Merino JL, Mont L, Prinzen F, Proclemer A, Pürerfellner H, Savelieva I, Schilling R, Steffel J, van Gelder IC, Zeppenfeld K, Zupan I, Heidbüchel H; ESC Scientific Document Group .

Europace. 2019 Mar 18. pii: euz055. doi: 10.1093/europace/euz055. [Epub ahead of print]

PMID:
30882143
9.

Left atrial ablation for management of atrial fibrillation: CABANA vs. real-world data. Apples and oranges?

Camm AJ.

Eur Heart J. 2019 Apr 21;40(16):1265-1267. doi: 10.1093/eurheartj/ehz168. No abstract available.

PMID:
30875420
10.

Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry.

Goto S, Angchaisuksiri P, Bassand JP, Camm AJ, Dominguez H, Illingworth L, Gibbs H, Goldhaber SZ, Goto S, Jing ZC, Haas S, Kayani G, Koretsune Y, Lim TW, Oh S, Sawhney JPS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK; GARFIELD‐AF Investigators.

J Am Heart Assoc. 2019 Feb 5;8(3):e010510. doi: 10.1161/JAHA.118.010510.

11.

The Cardiovascular Effects of a Meal: J-Tpeak and Tpeak -Tend Assessment and Further Insights Into the Physiological Effects.

Täubel J, Ferber G, Van Langenhoven L, Del Bianco T, Fernandes S, Djumanov D, Kanters JK, Graff C, Camm AJ.

J Clin Pharmacol. 2019 Jun;59(6):799-810. doi: 10.1002/jcph.1374. Epub 2019 Jan 11.

12.

Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation.

Bassand JP, Virdone S, Goldhaber SZ, Camm AJ, Fitzmaurice DA, Fox KAA, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK.

Circulation. 2019 Feb 5;139(6):787-798. doi: 10.1161/CIRCULATIONAHA.118.035012.

PMID:
30586740
13.

Atrial fibrillation: the era of scientific breakthrough.

Hindricks G, Savelieva I, Camm AJ.

Europace. 2018 Nov 1;20(FI_3):f275-f277. doi: 10.1093/europace/euy279. No abstract available.

PMID:
30481316
14.

Reply: Anticoagulants for Cardioembolism Prevention in Atrial Fibrillation Patients: Potential Bias From Real-World Studies.

Kirchhof P, Bach M, Camm AJ.

J Am Coll Cardiol. 2018 Nov 13;72(20):2546-2547. doi: 10.1016/j.jacc.2018.09.024. No abstract available.

PMID:
30442303
15.

Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study.

Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG, Camm AJ.

Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):70-79. doi: 10.1093/ehjcvp/pvy041.

PMID:
30423165
16.

[The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary].

Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H.

Kardiol Pol. 2018;76(9):1283-1298. doi: 10.5603/KP.2018.0180. Polish.

17.

XANAP: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia.

Kim YH, Shim J, Tsai CT, Wang CC, Vilela G, Muengtaweepongsa S, Kurniawan M, Maskon O, Li Fern H, Nguyen TH, Thanachartwet T, Sim K, Camm AJ; XANAP investigators.

J Arrhythm. 2018 Jul 6;34(4):418-427. doi: 10.1002/joa3.12073. eCollection 2018 Aug.

18.

Sta Ble Angina: Pe Rcept Ion of Nee Ds, Quality of Life and Mana Gem Ent of Patients (BRIDGE Study)-A Multinational European Physician Survey.

Ambrosio G, Collins P, Dechend R, Lopez-Sendon J, Manolis AJ, Camm AJ.

Angiology. 2019 May;70(5):397-406. doi: 10.1177/0003319718796313. Epub 2018 Aug 27.

PMID:
30149731
19.

Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS.

Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG.

Europace. 2019 Mar 1;21(3):421-427. doi: 10.1093/europace/euy160.

PMID:
30052894
20.

A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation.

Camm AJ, Dorian P, Hohnloser SH, Kowey PR, Tyl B, Ni Y, Vandzhura V, Maison-Blanche P, de Melis M, Sanders P.

Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):21-28. doi: 10.1093/ehjcvp/pvy022.

PMID:
30052825
21.

Diurnal Profile of the QTc Interval Following Moxifloxacin Administration.

Täubel J, Ferber G, Fernandes S, Camm AJ.

J Clin Pharmacol. 2019 Jan;59(1):35-44. doi: 10.1002/jcph.1283. Epub 2018 Jul 24.

PMID:
30040135
22.

Global Prospective Safety Analysis of Rivaroxaban.

Kirchhof P, Radaideh G, Kim YH, Lanas F, Haas S, Amarenco P, Turpie AGG, Bach M, Lambelet M, Hess S, Camm AJ; Global XANTUS program Investigators.

J Am Coll Cardiol. 2018 Jul 10;72(2):141-153. doi: 10.1016/j.jacc.2018.04.058.

23.

Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey).

Erküner Ö, Dudink EAMP, Nieuwlaat R, Rienstra M, Van Gelder IC, Camm AJ, Capucci A, Breithardt G, LeHeuzey JY, Lip GYH, Crijns HJGM, Luermans JGLM.

Am J Cardiol. 2018 Aug 15;122(4):578-583. doi: 10.1016/j.amjcard.2018.04.053. Epub 2018 May 11.

24.

Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants.

Camm AJ, Fox KAA.

Open Heart. 2018 Apr 21;5(1):e000788. doi: 10.1136/openhrt-2018-000788. eCollection 2018. Review.

25.

Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban.

Camm AJ, Fox KAA.

Curr Med Res Opin. 2018 Nov;34(11):1945-1957. doi: 10.1080/03007995.2018.1467885. Epub 2018 May 21.

PMID:
29672182
26.

Time trends in antithrombotic management of patients with atrial fibrillation treated with coronary stents: Results from TALENT-AF (The internAtionaL stENT - Atrial Fibrillation study) multicenter registry.

Potter BJ, Andò G, Cimmino G, Ladeiras-Lopes R, Frikah Z, Chen XY, Virga V, Goncalves-Almeida J, Camm AJ, Fox KAA.

Clin Cardiol. 2018 Apr;41(4):470-475. doi: 10.1002/clc.22898. Epub 2018 Apr 17.

27.

State of play and future direction with NOACs: An expert consensus.

Cohen AT, Lip GY, De Caterina R, Heidbuchel H, Zamorano JL, Agnelli G, Verheugt F, Camm AJ.

Vascul Pharmacol. 2018 Jul;106:9-21. doi: 10.1016/j.vph.2018.04.001. Epub 2018 Apr 12. Review.

PMID:
29656119
28.

The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease.

Camm AJ.

Thromb Haemost. 2018 May;118(S 01):S2-S11. doi: 10.1055/s-0038-1632387. Epub 2018 Mar 22.

PMID:
29566415
29.

Understanding the Value of Real-World Evidence: Focus on Stroke Prevention in Atrial Fibrillation with Rivaroxaban.

Camm AJ, Coleman CI, Larsen TB, Nielsen PB, Tamayo CS.

Thromb Haemost. 2018 May;118(S 01):S45-S60. doi: 10.1055/s-0038-1635084. Epub 2018 Mar 22.

PMID:
29566414
30.

The Evolution of Antithrombotic Care in Cardiovascular Patients.

Camm AJ.

Thromb Haemost. 2018 May;118(S 01):S1. doi: 10.1055/s-0038-1626720. Epub 2018 Mar 22. No abstract available.

PMID:
29566412
31.

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary.

Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Georg Haeusler K, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H; ESC Scientific Document Group.

Europace. 2018 Aug 1;20(8):1231-1242. doi: 10.1093/europace/euy054. Review.

PMID:
29562331
32.

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H; ESC Scientific Document Group .

Eur Heart J. 2018 Apr 21;39(16):1330-1393. doi: 10.1093/eurheartj/ehy136.

PMID:
29562325
33.

Electronic gadgets and their health-related claims.

Malik M, Camm AJ, Huikuri H, Lombardi F, Schmidt G, Schwartz PJ, Zabel M; e-Rhythm Study Group of EHRA.

Int J Cardiol. 2018 May 1;258:163-164. doi: 10.1016/j.ijcard.2018.02.032. No abstract available.

34.

Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care.

Kumar S, de Lusignan S, McGovern A, Correa A, Hriskova M, Gatenby P, Jones S, Goldsmith D, Camm AJ.

BMJ. 2018 Feb 14;360:k342. doi: 10.1136/bmj.k342.

PMID:
29444881
35.

Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference.

Kotecha D, Breithardt G, Camm AJ, Lip GYH, Schotten U, Ahlsson A, Arnar D, Atar D, Auricchio A, Bax J, Benussi S, Blomstrom-Lundqvist C, Borggrefe M, Boriani G, Brandes A, Calkins H, Casadei B, Castellá M, Chua W, Crijns H, Dobrev D, Fabritz L, Feuring M, Freedman B, Gerth A, Goette A, Guasch E, Haase D, Hatem S, Haeusler KG, Heidbuchel H, Hendriks J, Hunter C, Kääb S, Kespohl S, Landmesser U, Lane DA, Lewalter T, Mont L, Nabauer M, Nielsen JC, Oeff M, Oldgren J, Oto A, Pison L, Potpara T, Ravens U, Richard-Lordereau I, Rienstra M, Savelieva I, Schnabel R, Sinner MF, Sommer P, Themistoclakis S, Van Gelder IC, Vardas PE, Verma A, Wakili R, Weber E, Werring D, Willems S, Ziegler A, Hindricks G, Kirchhof P.

Europace. 2018 Mar 1;20(3):395-407. doi: 10.1093/europace/eux318.

36.

Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry.

Verheugt FWA, Gao H, Al Mahmeed W, Ambrosio G, Angchaisuksiri P, Atar D, Bassand JP, Camm AJ, Cools F, Eikelboom J, Kayani G, Lim TW, Misselwitz F, Pieper KS, van Eickels M, Kakkar AK; GARFIELD-AF Investigators.

Eur Heart J. 2018 Feb 7;39(6):464-473. doi: 10.1093/eurheartj/ehx730.

PMID:
29281086
37.

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

Fox KAA, Lucas JE, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Oto A, Mantovani LG, Misselwitz F, Piccini JP, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators.

BMJ Open. 2017 Dec 21;7(12):e017157. doi: 10.1136/bmjopen-2017-017157.

38.

International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.

Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, Ezekowitz MD, Fonarow GC, Gersh BJ, Goldhaber S, Haas S, Hacke W, Kowey PR, Ansell J, Mahaffey KW, Naccarelli G, Reiffel JA, Turpie A, Verheugt F, Piccini JP, Kakkar A, Peterson ED, Fox KAA; GARFIELD-AF; ORBIT-AF Investigators.

Am Heart J. 2017 Dec;194:132-140. doi: 10.1016/j.ahj.2017.08.011. Epub 2017 Aug 24.

39.

Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden.

Boriani G, Glotzer TV, Ziegler PD, De Melis M, Mangoni di S Stefano L, Sepsi M, Landolina M, Lunati M, Lewalter T, Camm AJ.

Heart Rhythm. 2018 Mar;15(3):376-383. doi: 10.1016/j.hrthm.2017.11.007. Epub 2017 Nov 7.

PMID:
29122724
40.

Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort.

Coughtrie AL, Behr ER, Layton D, Marshall V, Camm AJ, Shakir SAW.

BMJ Open. 2017 Oct 16;7(10):e016627. doi: 10.1136/bmjopen-2017-016627.

41.

Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention.

Camm AJ, Fox KAA, Peterson E.

Europace. 2018 Jan 1;20(1):1-11. doi: 10.1093/europace/eux086. Review.

PMID:
29040518
42.

The influence of progression of atrial fibrillation on quality of life: a report from the Euro Heart Survey.

Dudink EAMP, Erküner Ö, Berg J, Nieuwlaat R, de Vos CB, Weijs B, Capucci A, Camm AJ, Breithardt G, Le Heuzey JY, Luermans JGLM, Crijns HJGM.

Europace. 2018 Jun 1;20(6):929-934. doi: 10.1093/europace/eux217.

PMID:
29016989
43.

Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study.

Camm AJ, Turpie AGG, Hess S, Amarenco P, Lambelet M, Haas S, van Eickels M, Kirchhof P; XANTUS Investigators.

Europace. 2018 Jun 1;20(6):e87-e95. doi: 10.1093/europace/eux127.

PMID:
29016755
44.

Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Fox KAA, Accetta G, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Kayani G, Kakkar AK; GARFIELD-AF Investigators.

Eur Heart J Qual Care Clin Outcomes. 2018 Jan 1;4(1):27-35. doi: 10.1093/ehjqcco/qcx030.

PMID:
28950344
45.

Cardiac Potassium Channels: Physiological Insights for Targeted Therapy.

Jeevaratnam K, Chadda KR, Huang CL, Camm AJ.

J Cardiovasc Pharmacol Ther. 2018 Mar;23(2):119-129. doi: 10.1177/1074248417729880. Epub 2017 Sep 25. Review.

46.

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.

Kappos L, Arnold DL, Bar-Or A, Camm AJ, Derfuss T, Sprenger T, Davies M, Piotrowska A, Ni P, Harada T.

Mult Scler. 2018 Oct;24(12):1605-1616. doi: 10.1177/1352458517728343. Epub 2017 Sep 15.

47.

Atrial Fibrillation: Atrial High-Rate Events (AHRES): Look and You Will Find-Then What?

Waldo AL, Camm AJ.

Circulation. 2017 Nov 7;136(19):1795-1797. doi: 10.1161/CIRCULATIONAHA.117.030705. Epub 2017 Aug 28. No abstract available.

PMID:
28851730
48.

Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy.

Camm CF, Camm AJ.

Arrhythm Electrophysiol Rev. 2017 Jun;6(2):63-68. doi: 10.15420/aer.2017.4.2.

49.

European Heart Journal - Case Reports (EHJ-CR): a new format for an old concept.

Camm CF, Camm AJ.

Eur Heart J Case Rep. 2017 Aug 22;1(1):ytx001. doi: 10.1093/ehjcr/ytx001. eCollection 2017 Aug. No abstract available.

50.

Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.

Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E, Vardas P.

Am Heart J. 2017 Aug;190:12-18. doi: 10.1016/j.ahj.2017.04.015. Epub 2017 May 3.

Supplemental Content

Support Center